Results from a phase II basket trial displayed that Ado-trastuzumab emtansine provided a confirmed partial response rate of 44% (95% CI, 22%–69%) in 18 patients with advanced HER2-mutant lung adenocarcinomas and mPFS was 5 months (95% CI, 3–9 months). The gene discussed is ERBB2; the disease is lung adenocarcinoma.